Introduction
Globally, the estimated number of children younger than 15 years of age living with HIV in 2013 was 3.2 million, and an estimated 240,000 children were newly infected with HIV [1] . The introduction of highly active antiretroviral therapy (HAART) has resulted in a dramatic reduction in the morbidity and mortality rates in HIV-infected children [2] . In the USA and UK, a significant decline in mortality (81-93 %) has been reported in HIV-infected children between 1994 and 2006, while a significant decline in HIV-related morbidity and hospitalisations in children has been observed in the USA and Europe over the same time period [3] . Combined antiretroviral therapy (ART) or HAART regimens include at least three drugs from at least two drug classes of ART and have been associated with enhanced survival, reduction in opportunistic infections and other complications of HIV infection such as tuberculosis, cytomegalovirus infection, Kaposi's sarcoma and candidiasis, among others. They have also been shown to improve growth and neurocognitive function in children, resulting in an improved quality of life [3] .
Tenofovir disoproxil fumarate (TDF) is an orally bioavailable prodrug of tenofovir (also called 9-(R)-{2-(phosphonomethoxy)propyl}adenine or PMPA), which is principally eliminated by the kidneys [4] . It is a nucleotide reverse transcriptase inhibitor (NRTI) approved by the US Food and Drug Administration (FDA) in 2001. It is licensed as a once-daily 300 mg tablet for individuals aged 18 years and over for the treatment of HIV-1 infection in combination with other antiretrovirals [5] . TDF is recommended by the World Health Organisation (WHO) as one of the preferred NRTIs for first-line ART in individuals over 18 years of age and is available as a co-formulation with other antiretrovirals [6] . In March 2010, the FDA approved the 300 mg dose of TDF for use in adolescents aged 12-17 years [5, 7] . The safety profile observed from a phase III study of a TDF-containing antiretroviral regimen compared to an antiretroviral regimen containing zidovudine or stavudine in HIV-infected treatment-experienced children aged 2-12 years was consistent with that observed in clinical trials in adults. This provided evidence for use of TDF in children aged 2 to \12 years [5] . In January 2012, the FDA approved the use of TDF in combination with other antiretroviral agents for the treatment of HIV-1 infections in paediatric patients aged 2-12 years at a recommended dose of 8 mg/kg of body weight (up to a maximum of 300 mg) once daily, administered as an oral powder or tablets, based on the patient's age and weight [5] .
The efficacy of TDF in HIV-infected children has been demonstrated in some studies. Some small studies suggest that TDF was well-tolerated and effective in children [8, 9] . A retrospective cohort study of 159 treatment-experienced HIV-infected children in the UK and Ireland showed good efficacy, with 38 % attaining virological suppression at 12 months. The age range at first prescription of TDF was 9.3-13.7 years [10] . The safety and efficacy of TDF has not been established in children less than 2 years of age.
Preclinical studies have shown that the principal target organs of TDF toxicity are the gastrointestinal tract, kidneys and bone, but effects on the gastrointestinal system are mild [5] . HIV-associated abnormalities in growth factors and cytokines in HIV-infected children increases concerns about toxicities of HAART in the treatment of HIV. Limited studies of TDF in HIV-infected children have been performed and little is known about TDF toxicity in paediatric patients. The majority of TDF toxicities have been investigated in individuals over 18 years of age, but there are some recent data from studies in children and adolescents. Two studies in children receiving TDF as part of their HAART regimens showed a favourable safety profile for the drug [9, 11] , whereas renal toxicity mainly affecting the renal tubules has been described in some paediatric cohort studies [10, [12] [13] [14] . A further safety concern for TDF use in children is the potential for adverse effects on bone metabolism. Tenofovir-containing HAART is associated with [6 % loss in bone mineral density (BMD) in one-third of children. This tends to occur in heavily treatment-experienced prepubertal children or those in early puberty, and seems to recover partially with discontinuation of TDF [14, 15] .
This systematic review is aimed at identifying and summarising the reports of renal and bone adverse effects of a tenofovir-based regimen in HIV-infected children from 2 to 19 years of age.
Methods
A protocol for conducting the review was prepared using standard guidelines [16, 17] .
Eligibility Criteria
All primary studies that involved the use, safety, efficacy, adverse effects and toxicity of tenofovir in combination with other recommended antiretrovirals in the treatment of HIV infection in children from 2 to 19 years old were eligible. These included randomised controlled trials (RCTs), observational studies such as controlled and uncontrolled cohort studies, case-control studies, retrospective studies, case reports and pharmacovigilance data. This age group was considered based on the WHO definition of a child as a person 19 years or younger unless national law defines a person to be an adult at an earlier age; however, those aged 10-19 years are referred to as adolescents [6] . Studies with children younger than 2 years old were excluded because the safety and efficacy of tenofovir has not been established in children younger than 2 years of age [5] . Studies that involved the use of tenofovir for pre-and post-exposure prophylaxis, and treatment of chronic hepatitis B were also excluded.
Database Search and Study Selection
The following databases and platforms were searched by Rose I. Okonkwo (RIO) from 1 May 2014 to 18 [20] . Once all databases searches had been conducted, duplicate citations were identified and excluded using reference management software (RefWorks 2.0 [http://www.refworks.com/]). Following the removal of duplicate entries by RefWorks 2.0, the selection process was trialled by RIO by applying the inclusion criteria to ten of the identified papers in order to check that they can be reliably interpreted. Eligibility assessment and selection of included studies were performed independently by RIO and Emmanuel E. Effa (EEE).
Study selection was carried out by an initial screening of titles and then abstracts against the pre-specified eligibility criteria based on the review aim and the inclusion and exclusion criteria. Studies that were not relevant were excluded without reasons being recorded; those that addressed the topic of interest but failed on one or more criteria such as population were noted and reasons recorded. For studies that reported the same cohort, it was agreed that the earlier study or publication be considered and the others excluded. Studies that reported the absence of renal and bone adverse effects of TDF were excluded with documented reasons. For studies that appeared to meet the inclusion criteria, or in cases when a definite decision could not be made based on the title and/or abstract alone, the full papers were obtained for detailed assessment against the inclusion criteria. Instances where the full papers were unable to be retrieved were documented. Reference lists were scrutinised and any additional relevant titles included. The researchers RIO and EEE met to resolve any differences in their results.
Data Extraction
Data extraction tools were developed based on the Cochrane data collection form for intervention reviews for RCTs and non-RCTs, and these included information pertinent to the review aim. The data extraction sheet developed for this review was trialled by RIO on five randomly selected included studies (RCTs, non-RCTs and observational studies) and refined accordingly [17] . The relevant information extracted from the included studies (RCTs, non-RCTs and observational studies) were study characteristics (country of research, study design, sample size and duration of therapy), characteristics of participants (age, sex, viral load and CD4 cell count), therapeutic interventions and control regimen. Outcomes measures extracted included reports of renal and bone-related adverse effects, side effects, adverse events and/or adverse drug reactions of a TDF-containing regimen. Relevant data extracted from case reports and case series included age, therapeutic intervention and outcome measures. Also, the data extracted from the WHO Adverse Reaction Database were adverse drug reactions related to renal and bone adverse effects and the number of reports. Additional details on whether the drug reaction was suspected, caused by an interaction or as a result of concomitant use were also extracted. Data were extracted by RIO and validated by EEE.
Quality Assessment
The assessment of methodological quality of the included studies was performed using the Cochrane Collaboration's tool for assessing risk of bias for RCTs [16] and the Newcastle Ottawa Scale (NOS) for non-randomised studies [21] . To ascertain the validity of eligible RCTs, the adequacy of randomisation and concealment of allocation, blinding of patients, healthcare providers, data collectors and outcome assessors, and the extent of loss to follow-up were determined. To assess the quality of non-randomised studies using the NOS, studies were judged on three broad perspectives: the selection of the study groups; the comparability of the groups; and the ascertainment of either the exposure or outcome of interest for cohort studies. The quality of case reports and case series was not assessed as there is no generally acceptable tool for such studies.
Data Analysis
Due to differences in the study design, participants, background antiretroviral regimens and time of reporting of adverse effects, a meta-analysis was considered inappropriate. A narrative approach was used to highlight study findings [18, 22] .
Data analysis was categorised by study designs as data derived from divergent sources cannot be combined because of different study designs, different populations and different data collection methods [18] . These include analysis of: (a) RCTs; (b) Non-randomised and observational studies; and (c) Case reports and case series.
In addition, the results retrieved from the search of the WHO Adverse Reaction database were analysed.
Results

Preliminary Synthesis of Findings
Nineteen studies (two RCTs [23, 24] , nine non-randomised and observational studies [9, 10, 14, 15, [25] [26] [27] [28] [29] , four case reports [12, [30] [31] [32] and four case series [13, [33] [34] [35] ) that reported the presence of renal and bone adverse effects of a TDF-containing regimen were identified, including a total of 1100 study participants. The various study designs for the non-randomised and observational studies included three single-arm open-label trials [9, 14, 15] , two retrospective cohorts studies [10, 25] , one cross-sectional evaluation study [26] and three prospective cohort studies [27] [28] [29] , of which one involved retrospective and prospective data collections in a two-phase design. The total number of reported renal and bone adverse effects were 287 reports (250 renal and 37 bone adverse effects). Approximately 238 (21.6 %) participants were affected by these adverse effects. Of these, 15 stopped the TDF-containing regimen due to these adverse effects. The Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) flow chart [36] is given in Fig. 1 . The results of the quality assessment of the RCTs, non-randomised studies and observational studies are shown in a tabular form in Electronic Supplementary Material Tables 2 and 3 , respectively. Reporting of losses to follow-up and adverse events was adequate in all of these studies.
For the RCTs, non-randomised and observational studies, the median study duration was 96 weeks (range 48-308 weeks) and, for this analysis, this was considered equivalent to the time receiving treatment. The sample size ranged from 6 to 448 participants (median 70 participants). The studies varied greatly with respect to the specific antiretroviral drug used as comparator and antiretroviral co-interventions. In all of the studies reviewed that had comparators, TDF was not the only antiretroviral drug that differed between the treatment and control groups. However, despite the variations in ART combinations, each study allowed for comparison of an ART regimen containing TDF with a regimen not containing TDF. In addition, there were single-arm studies with no comparison. Seven studies [9, 10, 14, 15, 24, 25, 28] recruited only participants who were ART experienced, one study [28] included both ART-naive and ART-experienced participants and for three studies [25, 26, 29] this was unclear. The detailed characteristics of these studies are shown in a tabular form in Electronic Supplementary Material Table 4 . The mean age of participants across the included studies ranged from 7 to 16 years, and the proportion of participants who were male ranged from 42.9 to 66.7 % (median 47.5 %). The proportion of black participants ranged from 10 to 76.1 % (median 28.7 %). The baseline viral load, CD4 cell count and CD4 cell percentage were not available for some studies. The characteristics of participants included in these studies and the baseline parameters for the RCTs, non-randomised and cohort studies can be seen in Electronic Supplementary Material Table 5 .
For the case reports and case series, relevant data on age, treatment and outcomes (renal and bone adverse effects) were extracted (see Electronic Supplementary Material Table 6 ).
Analysis of Results
In this review, analysis of the results from adverse effects data were categorised by study design and summarised in a descriptive approach as the study designs and data varied markedly. Analysis of the results described the studies, the number and specific types of renal and bone adverse effects of a TDF-containing regimen, and the number of affected participants [17] . The analysis of the reported renal and bone adverse effects and the number of affected participants for the RCTs, non-randomised and observational studies, and case reports and case series is shown in Table 1 .
Analysis of Randomised Controlled Trials
The data on renal and bone adverse effects of TDF-containing regimen were identified and extracted from two RCTs [23, 24] that had a total of 187 study participants. There were twelve reported renal and bone adverse effects due to a TDF-based regimen in these studies (four renal and eight bone adverse effects) and a total of 11 participants were affected by these adverse effects. One RCT was aimed at the efficacy and safety of TDF in combination with an optimised background regimen (OBR) in treatment-experienced HIV-1-infected adolescents (12 to \18 years) with viraemia despite antiretroviral treatment [23] , and the other assessed the efficacy and safety of TDF in virologically suppressed, treatment-experienced HIV-infected children aged 2 to \16 years [24] . The study by Negra et al. [23] reported that one subject in the TDF group had acute renal failure not considered related to the study drug by the investigator after receiving amphotericin B for cryptococcosis, but none had a clinically relevant increase in serum creatinine related to TDF and no subject discontinued TDF due to renal events. However, in the placebo group, two subjects were reported to have nephrolithiasis and haematuria, both considered related to the study drug. The study only enrolled those with normal renal function and, therefore, the renal safety in adolescents with abnormal renal function was not assessed. Two subjects in the TDF group had fractures reported, both of which were trauma-related and not considered related to the study drug by the investigator. Six subjects in the TDF group had a significant decrease of spine BMD ([4.0 %) at week 48. Of the six subjects with a significant spine BMD decrease in the TDF group, one subject had an ankle fracture. One subject from the TDF group had significant decrease of total body BMD ([4.0 %) at week 48. However, in the placebo group, one subject had decreased total body BMD ([4.0 %). In the study by Saez-Llorens et al. [24] , no subjects discontinued the study drug due to an adverse event in the 48 weeks of the randomised phase. Four subjects discontinued due to either hypophosphataemia or glycosuria (considered to be clinically consistent with proximal renal tubulopathy) in the extension phase. All four subjects were taking lopinavir/ritonavir concomitantly with TDF at the time of discontinuation; however, no subject in the stavudine-or zidovudine-containing regimen group experienced any adverse effects. In the TDF group, three subjects experienced fractures during the extension phase, all of which were considered to be related to high-impact trauma.
Analysis of Non-Randomised and Observational Studies
The data of renal and bone adverse effects of TDF-containing regimen were identified and extracted from nine non-randomised and observational studies [9, 10, 14, 15, [25] [26] [27] [28] [29] that had a total of 901study participants. Not all of the non-randomised and observational studies reported the presence of renal and bone adverse effects of a TDF-containing regimen. There were 257 reported renal and bone adverse effects (232 renal and 25 bone adverse effects) and about 215 participants were affected by these adverse effects. ALP alkaline phosphatase, BMD bone mineral density, CKD chronic kidney disease, PRTD proximal renal tubular dysfunction
Renal Adverse Effects
Seven studies [10, 14, [25] [26] [27] [28] [29] reported renal adverse effects of a TDF-containing regimen (a total of 877 study participants). There were 232 reported renal adverse effects due to a TDF-based regimen in these studies, affecting 199 participants. These included 40 reports of proximal/renal tubular abnormalities, one report of renal failure, one report of Fanconi syndrome and one report of renal toxicity. There were 127 reports of proteinuria, eight reports of hypophosphataemia, one report of hypokalaemia and one report of haematuria and nephrocalcinosis (variably defined in each study). Twelve children had abnormally elevated b 2 -microglobulinuria ([350 lg/L), suggesting proximal renal tubular damage [26] . Chronic kidney disease was identified in 20 participants (the clinical diagnoses were nephropathy in seven subjects and nephrotic syndrome in one subject) [28] and one patient developed nephrolithiasis [14] . However, in one study [26] , the TDF-sparing group had two reports of abnormally elevated b 2 -microglobulinuria ([350 lg/L).
Bone Adverse Effects
Three studies (the singlearm open-label trials) reported bone adverse effects of a TDF-containing regimen [9, 14, 15] (a total of 43 study participants). There were 25 reported bone adverse effects due to a TDF-based regimen in these studies affecting 16 participants. Sixteen participants were reported to have absolute decreases in BMD. Of these, 12 participants had a [6 % decrease in BMD. Increased levels of bone-specific alkaline phosphatase were reported in four subjects and increased serum osteocalcin levels in five subjects. There were no reports of fracture in these studies.
Analysis of Case Reports and Case Series
There were four case reports [12, [30] [31] [32] and four case series [13, [33] [34] [35] in which participants were treated with a TDF-containing regimen. A total of 12 children were identified in the case reports and case series that specifically reported adverse effects. There were 18 reported renal and bone adverse effects due to a TDF-based regimen in these studies (14 renal and 4 bone adverse effects).
Analysis of Pharmacovigilance Data
The results of the search of WHO Adverse Reaction database were divided into three groups based on the WHO Adverse Reaction Terminology system-organ class (SOC) body organ groups. The results were stratified according to Adverse Drug Reaction-Preferred Term, reports indicated for HIV infection/AIDS and those whose indications are unclear. There were 101 reported adverse effects indicated for HIV/AIDS treatment and 48 reported renal and bone adverse effects of a TDF-based regimen for which the indication was unclear or not mentioned. Of the 101 reports indicated for HIV/AIDS, 88 were renal and 13 were bone adverse effects. For additional details on whether the drug reaction was suspected, caused by an interaction or as a result of concomitant use, see Electronic Supplementary Material Table 7 .
Renal Adverse Effects
There were 17 reports of renal tubular disorder, which was the most reported renal adverse effect. The second most reported renal adverse effects were hypophosphataemia and abnormal renal function, which had seven reported cases each. There were also cases of nephropathic toxicity (six reports), acute renal failure (two reports), chronic renal failure (three reports) and nephrogenic diabetes insipidus (two cases).
Bone Adverse Effects
Of the 13 reports of bone adverse effects of TDF, there were three cases of fractures, three cases of osteoporosis and one report of abnormal bone development.
Discussion
The most reported renal adverse effect was proximal renal tubulopathy, sometimes with Fanconi syndrome, occurring together with reduced glomerular filtration rate and reduced creatinine clearance. It is possible that detection of early or mild cases of TDF-associated nephrotoxicity would require testing for proximal tubule injury (e.g. urinalysis for proteinuria or glycosuria, measurement of bone density, serum phosphate level or bone fracture rate) [37] . Most of these cases involved the concomitant use of didanosine and/or a ritonavir-boosted protease inhibitor [10, 12, 13, 15, 24, 25, 27, [30] [31] [32] [33] 35] . Of the studies that reported these cases, some reported cases of higher than recommended doses of didanosine and/or a ritonavirboosted protease inhibitor used [10, 15] . Diabetes insipidus has been reported in children receiving a tenofovir-containing regimen including ritonavir-boosted lopinavir and didanosine [12, 30] . Irreversible renal failure has been reported in an adolescent with an underlying kidney disease and who was treated with a tenofovir regimen including ritonavir-boosted lopinavir but without didanosine [35] . It is important to note that the RCTs [23, 24] included in this review typically combined TDF with non-NRTI-based ART (rather than a ritonavir-boosted regimen and/or didanosine). The most commonly reported TDFassociated bone adverse effects was low BMD, which was seen in over 60 % of studies. The clinical implication of this remains unclear given the often short duration of many studies. Studies with a longer duration may be needed to evaluate clinically important complications [39] .
In some of the studies, accurate dosing was an important issue. This was a challenge as TDF was previously only available as a once-daily adult dose of 300 mg, but the children's formulation has now been made available by the manufacturer. Several studies [11, 14, 23, 24, [26] [27] [28] 38] have examined the effect of TDF on kidney function in HIV-infected children, including the two RCTs, with variable reports of evidence of renal impairment (including a decrease in the glomerular filtration rate, hypophosphataemia and proximal tubule dysfunction). In general, most of the studies have small sample sizes and are noncomparative, suggesting the need for adequately powered RCTs. Caution should therefore be exercised in interpreting results and larger studies are needed, ideally incorporating measures of both glomerular and tubular function [40] .
Toxicity affecting proximal tubular renal function and reduced bone mineralisation are serious concerns. Proximal tubular dysfunction causes a partial or complete Fanconi syndrome with metabolic acidosis and increased phosphate loss, both of which contribute to bone demineralisation. Tenofovir also reduces calcitriol synthesis in proximal tubular mitochondria, contributing to bone demineralisation [41] . BMD decline begins after 12-24 weeks and has been noted after up to 144 weeks on therapy. Children and young adolescents grow rapidly and bone mineralisation should peak with the pubertal growth spurt. Young children, especially those at Tanner Stage 1 and 2, are at higher risk of decreased BMD [42, 43] . Cumulative exposure to tenofovir has been associated with an increased risk of fractures in adults [44] , which may explain cases of fractures reported in children. However, not all studies of tenofovir in children have identified a decline in BMD [23, 45, 46] . No effect of tenofovir on BMD was found in a study in paediatric patients on stable therapy who had an undetectable viral load and who were switched from stavudine and protease inhibitor-containing regimens to tenofovir/lamivudine/efavirenz [45] . All patients in this study remained clinically stable and virologically suppressed after switching to the new regimen [47] . However, as with kidney function, studies on the effects of TDF exposure on bone health in HIV-infected children have generally involved small numbers of participants [14, 15, [48] [49] [50] , and have reported conflicting results. It is noteworthy that TDF is not unique in its ability to cause a reduction in BMD. HIV infection itself and many other antiretroviral drugs also cause a decline in BMD [51] [52] [53] [54] [55] . Vitamin D deficiency is common in children with HIV infection, and this may be an additional factor in the development of bone disease; supplementation may be required in some cases [40] .
The reported adverse effects underscore the need to monitor children closely with renal function tests at appropriate intervals. The availability of such facilities for frequent monitoring and the inherent tendency towards escalation of the cost of care in resource-constrained settings needs to be considered. As ART is often paid for by donor agencies, it is likely that such tests are not routinely performed for every child. Given that children will be on these medications for life, an extended period of monitoring for renal and bone adverse events will be necessary during the studies.
Limitations
Like all systematic reviews, the strength of our conclusions is limited by the available evidence. This systematic review does not perform a causality assessment of the renal and bone adverse effects of a TDF-containing regimen in HIVinfected children, rather only documenting the adverse effects that have been reported during its use. The information is subject to many potential sources of error, including the methods used to collect the adverse effects information. However, the method adopted for this review has helped ensure this is a complete and thorough summary of the published and unpublished literature on this topic. There was incomplete retrieval of studies identified during our search as five studies screened for titles and abstracts could not be accessed. In addition, the identified studies were of varied study designs and comparative studies were few and inadequately powered. When considering case reports and case series, it is important to note that these types of studies are only published when something happens and not when something does not happen, subjecting them to extreme publication bias.
Conclusion
There are uncertainties associated with the long-term effects of bone and renal toxicity. Moreover, the reversibility of renal toxicity cannot be fully ascertained. A multidisciplinary approach is recommended to address the risk/benefit balance of any TDF-containing treatment regimen on a case-by-case basis. This should include appropriate monitoring of renal and bone adverse effects during treatment (including the decision for treatment withdrawal) and the need for supplementation with vitamin D for bone health. Further research is needed, especially long-term studies that monitor clinically relevant markers of proximal tubulopathy and the impact of low BMD on the long-term risk of fragility fractures. In addition, future trials should focus on patients treated in resource-limited settings.
The importance of toxicity studies in HIV-infected children cannot be over-emphasised, particularly for children who may be adversely affected during growth and development and are likely to take ART for longer than adults. The magnitude of the renal and bone adverse effects is of clinical relevance, particularly for the renal adverse effects. This suggests the need for continued vigilance and efficient strategies for dissemination of the renal and bone adverse effects. The systematic review findings suggest that the benefits of using TDF in children need to be balanced against the potential risk of toxicity.
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